About Isofol

Isofol Medical AB (publ) aims to raise the quality of life and increase the survival rate for patients with severe forms of cancer. The company’s drug candidate arfolitixorin is being developed with the purpose of increasing the efficacy of standard first-line treatment for several forms of solid tumours, including colorectal cancer. The next step in the clinical development program is currently being prepared based on a new dosage regimen that is expected to optimize arfolitixorin’s efficacy.

Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

Read more >>

Upcoming Events

  • February 19, 2025 - February 19, 2025
    Year-end report 2024
  • April 09, 2025 - April 11, 2025
    Annual report 2024, published in week 15, April 2025
  • May 21, 2025 - May 21, 2025
    Interim report January-March 2025

FOLLOW US

Stay updated on the latest news by
following Isofol on Linkedin.

LinkedIn logotype
Scroll to Top